1834 Investment Advisors Co. Has $8.97 Million Holdings in Pfizer Inc. (NYSE:PFE)

1834 Investment Advisors Co. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 2.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 309,885 shares of the biopharmaceutical company’s stock after selling 6,247 shares during the quarter. Pfizer accounts for about 1.0% of 1834 Investment Advisors Co.’s portfolio, making the stock its 23rd largest holding. 1834 Investment Advisors Co.’s holdings in Pfizer were worth $8,968,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Marshall Wace LLP increased its position in shares of Pfizer by 279.3% in the second quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock worth $150,481,000 after purchasing an additional 8,378,173 shares during the period. Swedbank AB bought a new position in Pfizer in the 1st quarter valued at about $172,902,000. International Assets Investment Management LLC bought a new position in Pfizer in the 3rd quarter valued at about $146,481,000. 1832 Asset Management L.P. raised its position in shares of Pfizer by 24,961.6% in the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock valued at $69,891,000 after buying an additional 2,487,919 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its holdings in shares of Pfizer by 120.7% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 4,498,313 shares of the biopharmaceutical company’s stock worth $130,181,000 after acquiring an additional 2,459,666 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.98 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The firm has a market cap of $158.55 billion, a PE ratio of 37.81, a price-to-earnings-growth ratio of 0.89 and a beta of 0.67. The firm’s fifty day moving average is $28.99 and its 200-day moving average is $28.65.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.17) EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is presently 227.03%.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Citigroup initiated coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Eight analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.58.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.